Eyenovia halts Phase 3 myopia trial, to consider selling assets
Eyenovia stopped a Phase 3 trial following a review of the data that found its experimental myopia treatment wasn’t going to hit the study’s primary …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
